$CEMI can rise in the next days
Updated
Contextual immersion trading strategy idea.
Chembio Diagnostics has a strong upward trend.
The company develops, manufactures, and commercializes point-of-care diagnostic tests, in particular, COVID-19 tests.
This and other conditions can cause a rise in the share price in the next days.
I saw it again and opened a long position from $5,03;
stop-loss — $4,81.
Information about take-profits and stop-loss will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Chembio Diagnostics has a strong upward trend.
The company develops, manufactures, and commercializes point-of-care diagnostic tests, in particular, COVID-19 tests.
This and other conditions can cause a rise in the share price in the next days.
I saw it again and opened a long position from $5,03;
stop-loss — $4,81.
Information about take-profits and stop-loss will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Trade closed: stop reached
More information: fondexx.pro/
!!! Join our trader's chat !!!
Here ==> t.me/fndxworld
We build a cozy community of professional traders
!!! Join our trader's chat !!!
Here ==> t.me/fndxworld
We build a cozy community of professional traders
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.